Carnitine Deficiency: Primary and Secondary Syndromes

  • Giuseppe Famularo
  • Franco Matricardi
  • Eleonora Nucera
  • Gino Santini
  • Claudio De Simone
Part of the Molecular Biology Intelligence Unit book series (MBIU)


Emerging literature has shown that carnitine deficiency may be frequently recognized in human and the list of disorders associated with carnitine deficiency is growing.


Carnitine Palmitoyltransferase Free Carnitine Carnitine Deficiency Carnitine Level Carnitine Supplementation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Carter L, Abney TO, Lapp DF. Biosynthesis and metabolism of car-nitine. J Child Neurol 1995; 10 (Suppl):2S3–2S7.CrossRefGoogle Scholar
  2. 2.
    Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 1990; 28:297–301.PubMedGoogle Scholar
  3. 3.
    Virmani MA, Conti R, Spadoni A, Rossi S, Arrigoni Martelli E. Inhibition of L-carnitine uptake into primary rat cortical cell cultures by GABA and GABA uptake blockers. Pharmacol Res 1995; 31:211–215.PubMedCrossRefGoogle Scholar
  4. 4.
    Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995; 10 (Suppl):2S8–2S21.Google Scholar
  5. 5.
    Di Donato S, Garavaglia B, Rimoldi M, Carrara F. Clinical and bio-medical phenotypes of carnitine deficiencies. In:Ferrari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992:81–98.Google Scholar
  6. 6.
    Miyagawa J, Kuwajima M, Hanafusa T et al. Mitochondrial abnor malities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. Virchows Arch 1995; 426:271–279.PubMedCrossRefGoogle Scholar
  7. 7.
    Weaver LT, Rosenthal SR, Gladstone W, Winter HS. Carnitine deficiency: A possible cause of gastrointestinal dysmotility. Acta Pediatr 1992; 81:79–81.CrossRefGoogle Scholar
  8. 8.
    Regitz-Zagrosek V, Fleck E. Myocardial carnitine deficiency in human cardiomyopathy. In: tDe Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:145–166.Google Scholar
  9. 9.
    Bennett MJ, Hale DE. Defects of mitochondrial beta-oxidation enzymes. In: Ferrari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992:187–206.Google Scholar
  10. 10.
    Regitz V, Fleck E. Role of carnitine in heart failure. In: Ferrari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992:295–323.Google Scholar
  11. 11.
    Patel AK, Thomsen JH, Kosolcharoen PK, Shug AL. Myocardial carnitine status: clinical, prognostic and therapeutic significance. In: Ferrari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992:325–335.Google Scholar
  12. 12.
    Arduini A, Dottori S, Molajoni F, Kirk R, Arrigoni Martelli E. Is the carnitine system part of the heart antioxidant network? In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutic Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:169–181.Google Scholar
  13. 13.
    Fernandez C. Profile of long-term L-carnitine therapy in cardiopathic patients. In: Ferrari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992:337–341.Google Scholar
  14. 14.
    Rizos I, Primikiropoulos A, Hadjinikolau L et al. Hemodynamical effects of L-carnitine on patients with congestive heart failure due to dilated cardiomyopathy. Eur Heart J 1995; 16:181.Google Scholar
  15. 15.
    Broderick TL, Panagakis P, Di Domenico et al. L-carnitine improvement of cardiac function is associated with a stimulation in glucose but not fatty acid metabolism in carnitine-deficient rats. Cardiovasc Res 1995; 30: 815–820.PubMedGoogle Scholar
  16. 16.
    Rizos I, Primikiropoulos A, Hadjinikolau L et al. Effect of L-carnitine on plasma renin activity on patients with severe and moderate heart failure. European Society of Cardiology, Amsterdam, The Netherlands, August 20–24th, 1995. (Abstract)Google Scholar
  17. 17.
    Famularo G, De Simone C. A new era for carnitine? Immunol Today 1995.Google Scholar
  18. 18.
    Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1991; 323:236–240.CrossRefGoogle Scholar
  19. 19.
    Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease (5th edition). Philadelphia: W.B. Saunders, 1997: 394–420.Google Scholar
  20. 20.
    Ferrari R, Anand I. Utilization of propionyl-L-carnitine for the treatment of heart failure. In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995: 323–335.Google Scholar
  21. 21.
    Caponnetto S, Brunelli C. Hemodynamic and metabolic effect of propionyl-L-carnitine in patients with heart failure. In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:337–351.Google Scholar
  22. 22.
    Ferrari R, Pasini E, Condorelli E et al. Effect of propionyl-L-carnitine on mechanical function of isolated rabbit heart. Cardiovasc Drugs Ther 1991; 5 (Suppl l):17–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Paulson DJ, Shug AL. Experimental evidence of the anti-ischemic effect of L-carnitine. In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:183–197.Google Scholar
  24. 24.
    Pepine CJ, Welsch MA. Therapeutic potential of L-carnitine in patients with angina pectoris. In: De Jong JW, Ferrari R, eds. The Car-nitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:225–243.Google Scholar
  25. 25.
    Rizzon P, Di Biase M, Biasco G, Pitzalis MV. Carnitine and myocar-dial infarction. In: De Jong RW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:245–249.Google Scholar
  26. 26.
    Fritz IB, Arrigoni Martelli E. Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci 1995; 14:355–360.CrossRefGoogle Scholar
  27. 27.
    Broderick TL, Quinney HA, Lopaschuk GD. L-carnitine increases glucose metabolism and mechanical function following ischemia in diabetic rat heart. Cardiovasc Res 1995; 29:373–378.PubMedGoogle Scholar
  28. 28.
    Kressig R. L-carnitine in the treatment of stable angina pectoris. Ars Med 1995; 85:200–202.Google Scholar
  29. 29.
    Watanabe S, Ajisaka R, Masuoka T et al. Effects of L-and DL-car-nitine on patients with impaired exercise tolerance. Jpn Heart J 1995; 36:319–331.PubMedCrossRefGoogle Scholar
  30. 30.
    Watanabe S, Ajisaka R, Eda K et al. Effects of L-carnitine on patients with ischemic heart disease evaluated by myocardial SPECT with 1231-beta-methyl iodophenyl pentadecanoic acid (BMIPP). J Nucl Cardiol 1995; 2:S47 (Abstract).Google Scholar
  31. 31.
    Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72:45–50.PubMedCrossRefGoogle Scholar
  32. 32.
    Iliceto S, Scrutinio D, Bruzzi P et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-carnitine Ecografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 1995; 26:380–387.PubMedCrossRefGoogle Scholar
  33. 33.
    Madden MC, Wolkowicz PE, Pohost GM, McMillin JB, Pike MM. Acylcarnitine accumulation does not correlate with reperfusion recovery in palmitate-perfused rat hearts. Am J Physiol 1995; 268:2505–2512.Google Scholar
  34. 34.
    Knabb MT, Russell BA. Inhibition of cardiac carnitine palmitoyltransferase I activity with antiarrythmic drugs. J Pennsylvania Acad Sci 1995; 69:49–52.Google Scholar
  35. 35.
    Paulson DJ, Sanjak M, Shug AL. Carnitine deficiency and the diabetic heart. In: Lee Carter A, ed. Current Concepts in Carnitine Research. Boca Raton: CRC Press, 1992; 215–230.Google Scholar
  36. 36.
    Feuvray D. Carnitine metabolism during diabetes and hyperthyroidism. In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:199–208.Google Scholar
  37. 37.
    Broadway NM, Saggerson ED. Inhibition of liver microsomal carnitine acyltransferases by sulphonylurea drugs. FEBS Lett 1995; 371:137–139.PubMedCrossRefGoogle Scholar
  38. 38.
    Schmitz FJ, Rosen R, Reinauer H. Improvement of myocardial function and metabolsim in diabetic rats by the carnitine palmitoyltransferase inhibitor etoximir. Horm Metab Res 1995; 27:515–522.PubMedCrossRefGoogle Scholar
  39. 39.
    Ahmad S. Carnitine, kidney and renal dialysis. In: Ferari R, Di Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: from Function to Therapy. London: Academic Press, 1992; 381–400.Google Scholar
  40. 40.
    Ayer SB, Montemeyer L, Delauder D. Incidence and pattern of carnitine deficiency in a free standing dialysis unit. J Am Soc Nephrol 1995; 6:572 (Abstract).Google Scholar
  41. 41.
    Lago M, Perez Garcia R, Arenas J et al. Carnitine losses in hemodialysis: influence of different membrane-dialyzers and relationship with nutritional status. Nefrologia 1995; 15:55–61.Google Scholar
  42. 42.
    Borum P, Ross E. Altered plasma and red-cell carnitine status in hemodialysis-patients correlates with anemia. FASEB J 1995; 9:156 (Abstract).Google Scholar
  43. 43.
    De Los Reyes B, Garcia RP. Effects of low intravenous dose of L-carnitine in patients on hemodialysis. Kidney Int 1995; 48:284 (Abstract).Google Scholar
  44. 44.
    Kandemir EG, Evrenkaya TR, Cebeci BS, Ozcan A, Tulbek MY. Effect of L-carnitine on lipid abnormalities and cardiac dysfunctions in chronic hemodialysis patients. Bull Gulhane Mil Med Acad 1995; 37:441–447.Google Scholar
  45. 45.
    Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26:757–764.PubMedCrossRefGoogle Scholar
  46. 46.
    Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis-patients. Clin Ther 1995; 17:176–185.PubMedCrossRefGoogle Scholar
  47. 47.
    Kavadias D, Fourtounas C, Tsouchnikas J, Vlachonasios T, Barboutis K. Reduction of the cost of erythropoietin therapy by coadmini-stration of L-carnitine in hemodialysis patients. Nephrol Dial Transplant 1995; 10:1047 (Abstract).Google Scholar
  48. 48.
    Sloan RS, Smith B, Golper TA. The intradialytic effects of oral L-carnitine: results of a double-blind, placebo-controlled trial. J Am Soc Nephrol 1995; 6:588 (Abstract).Google Scholar
  49. 49.
    Suleymaniar G, Yilmaz H, Coskun M, Ersoy F, Yegin O, Yakupoglu G. The beneficial effect of L-carnitine on neutrophil chemotaxis in chronic renal failure patients on hemodialysis (HD). Nephrol Dial Transplant 1995; 10:1025 (Abstract).Google Scholar
  50. 50.
    Kirby DPJ, Constantin Teodosiu D, Short AH et al. Free and total carnitine concentrations in continuous ambulatory peritoneal dialysis patients. Proceedings of the Nutrition Society 1995; 54:4 (Abstract).Google Scholar
  51. 51.
    Bakker SJL, Yin M, Koostra G. Tissue thiamine and carnitine deficiency as a possible cause of acute tubular necrosis after renal transplantation. Transplant Proc 1996; 28:314–315.PubMedGoogle Scholar
  52. 52.
    Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response: evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995; 59:565–572.PubMedGoogle Scholar
  53. 53.
    Hammerman MR, Miller SB. Therapeutic use of growth factors in renal failure. J Am Soc Nephrol 1994; 5:1–11.PubMedGoogle Scholar
  54. 54.
    Safirstein RL, Bonventre JV. Molecular response to ischemic and nephrotoxic acute renal failure. In: Schlondorff D, Bonventre JV, eds. Molecular Nephrology: Kidney Function in Health and Disease. New York: Marcel Dekker, 1995, 839–854.Google Scholar
  55. 55.
    Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. Ann Intern Med 1996; 125:865–872.PubMedGoogle Scholar
  56. 56.
    De Simone C, Tzantzoglou S, Famularo G et al. High dose L-car-nitine improves immunologie and metabolic parameters in AIDS patients. Immunopharmacol Immunotoxicol 1993; 15:1–12.PubMedCrossRefGoogle Scholar
  57. 57.
    De Simone C, Famularo G, Tzantzoglou S et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS 1994; 8:655–660.PubMedCrossRefGoogle Scholar
  58. 58.
    Gonzalez-Crespo M, Arenas J, Cabello A et al. Free carnitine and carnitine esters levels in muscle of patients with idiopathic inflammatory myositis. Arthritis Rheum 1995; 38:9 (Abstract).CrossRefGoogle Scholar
  59. 59.
    Famularo G, De Simone C, Arrigoni Martelli E, Jirillo E. Carnitine and septic shock: a review. J Endotoxin Res 1995; 2:141–147.Google Scholar
  60. 60.
    Winter BK, Fiskum G, Gallo LL. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 1995; 72:1173–1179.PubMedCrossRefGoogle Scholar
  61. 61.
    Delogu G, De Simone C, Famularo G, Fegiz A, Paoletti F, Jirillo E. Anaesthetics modulate tumour necrosis factor alpha: effects of L-carnitine supplementation in surgical patients. Preliminary results. Med Inflamm 1993; 2 (Suppl):S33–S36.Google Scholar
  62. 62.
    Hayashi N, Yoshihara D, Kashiwabara N, Takeshita Y, Handa H, Yamakawa M. Effect of carnitine on decrease of branched chain amino acids and glutamine in serum of septic rats. Biol Pharm Bull 1996; 19:157–159.PubMedCrossRefGoogle Scholar
  63. 63.
    Linz DN, Garcia VF, Arya G et al. Weanling and adult rats differ in fatty acid and carnitine metabolism during sepsis. J Pediatr Sur 1995; 30:959–966.CrossRefGoogle Scholar
  64. 64.
    Aviles A, Arevila N, Diaz-Maquero JC, Gomez T, Garcia R, Nambo MJ. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxan-trone therapy for Hodgkin’s disease in adults. Leuk Lymphomas 1993; 11:275–279.CrossRefGoogle Scholar
  65. 65.
    Cierpka D. Carnitene (Sigma Tau) in acquired carnitine deficiency. Sigma-Tau Pharma Ltd., Pomezia (Italy), 1994.Google Scholar
  66. 66.
    Lee Carter A, Pierce R, Culbreath C, Howard E. Conjunctive enhancement of adriamycin by carnitine. In: Lee Carter A, ed. Current Concepts in Carnitine Research. Boca Raton: CRC Press, 1992, 245–251.Google Scholar
  67. 67.
    Battelli D, Bobyleva V, Ballei M, Arrigoni Martelli E, Muscatello U. Interaction of carnitine with mitochondrial cardiolipin. Biochim Bophys Acta 1992; 1117:33–36.CrossRefGoogle Scholar
  68. 68.
    Schlenzig JS, Charpentier C, Rabier D, Kamoun P, Sewell AC, Harpey JP. L-carnitine: a way to decrease cellular toxicity of ifosfamide? Eur J Pediatr 1995:154:686–687.PubMedCrossRefGoogle Scholar
  69. 69.
    Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment. J Child Neurol 1995; 10 (Suppl):2S32–2S39.Google Scholar
  70. 70.
    Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitamin Nutr Res 1995; 65:211–214.Google Scholar
  71. 71.
    Tein I, Di Mauro S, Xie ZW, De Vivo DC. Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. J Inherit Metab Dis 1995; 18:313–322.PubMedCrossRefGoogle Scholar
  72. 72.
    Gidal B, Rust RS, Inglese CM et al. Effect of carnitine supplementation on valproate-mediated transient hyperammonemia in children. Epilepsia 1995; 36:533 (Abstract).Google Scholar
  73. 73.
    Delgado MR, Liu H, Mills J, Browne R. Effect of L-carnitine supplementation on the platelet count of children with epilepsy with high valproate dose and/or serum levels. Epilepsia 1995; 36:68 (Abstract).Google Scholar
  74. 74.
    Holme E, Jodal U, Lindstedt S, Nordin I. Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. Scand J Clin Lab Invest 1992; 52:361–372.PubMedCrossRefGoogle Scholar
  75. 75.
    Nakashima M, Uematsu T, Oguma T et al. Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple administration study with special emphasis on the influence on carnitine body stores. Antimicrob Agents Chemother 1992; 36:762–768.PubMedGoogle Scholar
  76. 76.
    Shimizu K, Saito A, Yamamoto S. Carnitine status and safety after administration of S-1108, a new oral cephem to patients. Antimicrob Agents Chemother 1993; 37:1043–1049.PubMedGoogle Scholar
  77. 77.
    Rose SJ, Stokes TC, Patel S, Cooper MB, Betteridge DJ, Payne JE. Carnitine deficiency associated with long-term pivampicillin treatment: the effect of a replacement therapy regimen. Postgrad Med J 1992; 68:932–934.PubMedCrossRefGoogle Scholar
  78. 78.
    Abrahamsson K, Holme E, Jodal U, Lindstedt S, Nordin I. Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration: a risk irrespective of age. Bioch Mol Med 1995; 55:77–79.CrossRefGoogle Scholar
  79. 79.
    Diep QN, Böhmer T. Increased pivaloylcarnitine in the liver of the sodium pivalate-treated rat exposed to clofibrate. Biochim Biophys Acta 1995; 1256:245–247.PubMedGoogle Scholar
  80. 80.
    Davis AT. Carnitine depletion in rat pups of lactating mothers given sodium pivalate. Biol Neonate 1995; 68:211–220.PubMedCrossRefGoogle Scholar
  81. 81.
    Broderick TL, Christos SC, Wolf BA, Di Domenico D, Shug AL, Paulson DJ. Fatty acid oxidation and cardiac function in the sodium pivalate model of secondary carnitine deficiency. Metab Clin Exp 1995; 44:499–505.PubMedCrossRefGoogle Scholar
  82. 82.
    Abrahamsson K, Mellaner M, Eriksson BO et al. Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid. Br Heart J 1995; 74:656–659.PubMedCrossRefGoogle Scholar
  83. 83.
    Morris GS, Zhou Q, Wolf BA et al. Sodium pivalate reduces cardiac carnitine content and increases glucose oxidation without affecting cardiac functional capacity. Life Sci 1995; 57:2237–2244.PubMedCrossRefGoogle Scholar
  84. 84.
    Tune BM, Hsu CY. Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: structure-activity relationships. J Pharmacol Exp Ther 1994; 270:873–880.PubMedGoogle Scholar
  85. 85.
    Tune BM, Hsu CY. Toxicity of cephalosporins to fatty acid metabolism in rabbit renal cortical mitochondria. Biochem Pharmacol 1995; 49:727–734.PubMedCrossRefGoogle Scholar
  86. 86.
    Sekas G, Paul HS. Hyperammonemia and carnitine deficiency in a patient receiving sulfadiazine and pyrimethamine. Am J Nutr 1995; 95:112–113.Google Scholar
  87. 87.
    Kuntzer T, Reichmann H, Bogousslavsky J. Emetine-induced myopathy and carnitine deficiency. J Neurol 1990; 237:495–496.PubMedCrossRefGoogle Scholar
  88. 88.
    Sakuma T, Asai K, Ichiki T, Sugiyama N, Kidouchi K, Wada Y. Identification of benzoylcarnitine in the urine of a patient of hyperammonemia. Tohoku J Exp Med 1989; 159:147–151.PubMedCrossRefGoogle Scholar
  89. 89.
    Ratnakumari L, Quershi IA, Butterworth RF. Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperam-monemic mice and its role during benzoate therapy. Metabolism 1993; 42:1039–1046.PubMedCrossRefGoogle Scholar
  90. 90.
    Ali A, Qureshi IA. Benzoyl-CoA ligase activity in the liver and kidney cortex of weaning guinea-pigs treated with various inducers-relationship with hippurate synthesis and carnitine levels. Dev Pharmacol Ther 1992; 18:55–64.PubMedGoogle Scholar
  91. 91.
    Sakuma T. Alteration of urinary carnitine profile induced by benzoate administration. Arch Dis Child 1991; 66:873–875.PubMedCrossRefGoogle Scholar
  92. 92.
    Michalak A, Qureshi IA. Tissue acylcarnitine and acylcoenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine. Biomed Pharmacother 1995; 49:350–357.PubMedCrossRefGoogle Scholar
  93. 93.
    Deufel TH, Siegert W, Pongratz D, Jacob K, Wieland OH. Myopathic carnitine deficiency associated with lymphocytic malignant non-Hodgkin lymphoma and immunoglobulin G-k. Klin Wschr 1984; 62:669–674.PubMedCrossRefGoogle Scholar
  94. 94.
    Ferrari L, Maccari F, Chiodi P, Ramacci MT, De Angelis C, Angelucci L. Lidocaine-induced reduction in carnitine levels and morphological muscular alterations. Pharmacol Res 1990; 22 (Suppl 2): 197 (Abstract).CrossRefGoogle Scholar
  95. 95.
    Rossignoli L, Bertini L, Molino FM et al. L-carnitine combined with various anesthesiological techniques: its role in the development of endocrine-metabolic response to surgical stress. Alim Nutr Metab 1992; 13:57–67.Google Scholar
  96. 96.
    Pessotto P, Liberati R, Petrella O, Hulsmann WC. Quaternary nitrogen compounds affect carnitine distribution in rats. Particular emphasis on edrophonium. Biochim Biophys Acta Lipids Lipid Metab 1996; 1299:245–251.CrossRefGoogle Scholar
  97. 97.
    Rebouche CJ. The ability of guinea pigs to synthesize carnitine at a normal rate from epsilon-N-trimethyllysine or gamma butyrobetaine in vivo is not compromised by experimental vitamin C deficiency. Metab Clin Exp 1995; 44:624–629.PubMedCrossRefGoogle Scholar
  98. 98.
    Rebouche CJ. Renal handling of carnitine in experimental vitamin C deficiency. Metab Clin Exp 1995; 44:1639–1643.PubMedCrossRefGoogle Scholar
  99. 99.
    Bartels GL, Remme WJ, Schölte HR. Acute myocardial ischemia induces cardiac carnitine release in man. Eur Heart J 1997; 18:84–90.PubMedGoogle Scholar

Copyright information

© Landes Bioscience 1997

Authors and Affiliations

  • Giuseppe Famularo
  • Franco Matricardi
  • Eleonora Nucera
  • Gino Santini
  • Claudio De Simone

There are no affiliations available

Personalised recommendations